Specific method of prostate cancer detection based on pca3 gene, and kits therefor
CA 2530646 C · Owner: Hessels, Daphne · Inventors: Hessels, Daphne; Verhaegh, Gerald; Smit, Frank
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates, in general to prostate cancer. More , specifically the present invention relates to a method to diagnose prostate cancer in a, patient by detecting a PCA3 sequence and more particularly a , PCA3 RNA, the PCA3 sequence detected in a sample from the patient being specifically associated with prostate cancer. In a particular embodiment the method and kit enables an amplification of a PCA3 RNA through an exon-exon junction of a spliced PCA3 mRNA. The invention also related to methods and kits to detect such an amplified PCA3 RNA using a probe which spans the , amplified exonexon junction. The invention also relates to kits containing nucleic acid primers and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 30, 2004 and granted November 3, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 30, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 30, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.